153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma

Haematologica. 2004 Sep;89(9):ECR36.
No abstract available

Publication types

  • Case Reports
  • Evaluation Study

MeSH terms

  • Fatal Outcome
  • Graft Survival
  • Humans
  • Male
  • Melphalan / therapeutic use
  • Multiple Myeloma / complications
  • Multiple Myeloma / radiotherapy*
  • Multiple Myeloma / surgery
  • Organometallic Compounds / pharmacokinetics
  • Organometallic Compounds / therapeutic use*
  • Organophosphorus Compounds / pharmacokinetics
  • Organophosphorus Compounds / therapeutic use*
  • Osteolysis / etiology
  • Osteolysis / radiotherapy
  • Peripheral Blood Stem Cell Transplantation*
  • Radioisotopes / pharmacokinetics
  • Radioisotopes / therapeutic use*
  • Radiopharmaceuticals / pharmacokinetics
  • Radiopharmaceuticals / therapeutic use*
  • Salvage Therapy*
  • Samarium / pharmacokinetics
  • Samarium / therapeutic use*
  • Transplantation Conditioning
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Organometallic Compounds
  • Organophosphorus Compounds
  • Radioisotopes
  • Radiopharmaceuticals
  • (ethylenedinitrilo)-tetramethylenephosphonic acid
  • Samarium
  • samarium Sm-153 lexidronam
  • Melphalan